European medicines agency. https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty. Accessed 2 Dec 2022.
Ministero della Salute. https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&codLeg=84353&parte=1%20&serie=null. Accessed 12 Feb 2022.
Borgsteede SD, Geersing TH, Tempels-Pavlica Ž. Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines. Allergy. 2021;76:1941–2.
Hause AM, Baggs J, Marquez P, Myers TR, Gee J, Su JR, et al. COVID-19 vaccine safety in children aged 5-11 years – United States, November 3-December 19, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1755–60.
Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021;9:3546–67.
Tuyls S, Van Der Brempt X, Faber M, Gadisseur R, Dezfoulian B, Schrijvers R, et al. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BelSACI). Acta Clin Belg. 2021;1:1–6. https://doi.org/10.1080/17843286.2021.1909447. Epub ahead of print.
Vander Leek TH, Chan ES, Connors L, Derfalvi B, Ellis AK, Upton JEM, et al. COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol. 2021;17:29.
Kim MA, Lee YW, Kim SR, Kim JH, Min TK, Park HS, et al. COVID-19 vaccine-associated anaphylaxis and allergic reactions: consensus statements of the KAAACI Urticaria/angioedema/anaphylaxis working group. Allergy Asthma Immunol Res. 2021;13:526–44.
Worm M, Bauer A, Wedi B, Treudler R, Pfuetzner W, Brockow K, et al. Practical recommendations for the allergological risk assessment of the COVID-19 vaccination – a harmonized statement of allergy centers in Germany. Allergologie. 2021;5:72–6.
Turner PJ, Ansotegui IJ, Campbellc DE, Cardona V, Ebisawa M, El-Gamal Y, et al. On behalf of the WAO anaphylaxis committee. COVID-19 vaccine-associated anaphylaxis: a statement of the world allergy organization anaphylaxis committee. World Allergy Organ J. 2021;14:100517.
Tanno KS, Berard F, Beaudoin F, Didier A, Demoly P. On behalf of the Montpellier WHO collaborating center and French allergy Society (SFA). SARS-CoV-2 vaccination and anaphylaxis: recommendations of the French allergy community and the Montpellier World Health Organization collaborating center. Vaccines. 2021;9:560.
Murphy KR, Patel NC, Ein D, Hudelson M, Kodoth S, Gailen D, et al. Insights from American College of Allergy, Asthma, and Immunology COVID-19 Vaccine Task Force: Allergic Reactions to mRNA SARS-CoV-2 Vaccines. Ann Allergy Asthma Immunol. 2021;126:319–20.
Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. EAACI statement on the diagnosis, management, and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021;76:1629–39.
Barbaud A, Garvey LH, Arcolaci A, Brockow K, Mori F, Mayorga C, et al. Allergies and COVID-19 vaccines: an ENDA/EAACI position paper. Allergy. 2022. https://doi.org/10.1111/all.15241. Online ahead of print.
Tosca M, Miraglia Del Giudice M, Cardinale F, Licari A, Caffarelli C, Cravidi C, Calvani M, Martelli A, Chiappini E, Manti A, Novembre E, Marseglia GL. Gestione della vaccinazione per COVID-19 in soggetti di età 12–18 anni con allergie, asma, anafilassi e immunodeficienze SIAIP Novembre 2021. https://www.siaip.it/site/sezione/3/area/2/Medico%20Documenti.
AAIITO/SIAAIC Linee di indirizzo per la gestione da parte degli allergologi dei pazienti a rischio di reazioni allergiche ai vaccini per COVID-19 Versione 15/02/21. https://www.siaip.it/site/sezione/3/area/2/Medico%20Documenti.
Gallo G, Mel R, Ros E, Filia A. Guida alle controindicazioni alle vaccinazioni, quinta edizione – febbraio 2018 Ministero della Sanità. https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2759.
Jutel M, Torres MJ, Palomares O, Akdis CA, Eiwegger T, Untersmayr E, et al. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations. Allergy. 2022. https://doi.org/10.1111/all.15252. Online ahead of print.
Turner PJ, Worm M, Ansotegui IJ, El-Gamal Y, Rivas MF, Fineman S, et al. Time to revisit the definition and clinical criteria for anaphylaxis? World Allergy Organ J. 2019;12:100066.
ASCIA, Allergy, Immunodeficiency, autoimmunity and COVID-19 vaccination position statement updated 20 2021. https://www.allergy.org.au/hp/papers/ascia-hp-position-statement-covid-19-vaccination.
CDC. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:46–51.
Hashimoto T, Ozaki A, Bhandari D, Sawano T, Sah R, Tanimoto T. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data. J Travel Med. 2021;28:taab090.
Liotti L, Bianchi A, Bottau P, Caimmi S, Crisafulli G, Franceschini F, et al. COVID-19 vaccines in children with cow’s milk and food allergies. Nutrients. 2021;13:2637.
Alhumaid S, Mutair AA, Al Alawi Z, Rabaan AA, Tirupathi R, Alomari MA, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021;17:109.
Bonadonna P, Brockow K, Niedoszytko M, Elberink HO, Akin C, Nedoszytko B, et al. COVID-19 vaccination in Mastocytosis: recommendations of the European competence network on Mastocytosis (ECNM) and American initiative in mast cell diseases (AIM). J Allergy Clin Immunol Pract. 2021;9:2139–44.
Banerji A, Wickner PG, Saff R, Stone CA Jr, Robinson LB, Long AA, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9:1423–37.
Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326:1390–13.
Milota T, Strizova Z, Smetanova J, Sediva A. An immunologist’s perspective on anti-COVID-19 vaccines. Curr Opin Allergy Clin Immunol. 2021;21:545–52.
Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. 2021;148:739–49.
Delmonte OM, Bergerson JRE, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticardo M, et al. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. J Allergy Clin Immunol. 2021;148:1192–7.
Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno C, Medri C, et al. Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies. Front Immunol. 2021;12:727850.
Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate V, Lang H, Lazarski CA, et al. Robust antibody and T cell responses to SARS-CoV-2 in patients with antibody deficiency. J Clin Immunol. 2021;41:1146–53.
Paediatric Reumathology European Society. PRES update regarding COVID-19 vaccination in children with rheumatic diseases. https://www.pres.eu/clinical affairs/guidelines.html .
Poussaint TY, La Rovere KL, Newyrgwe JW, Chou J, Nigrovic LE, Novak T, et al. Multisystem inflammatory-like syndrome in a child following COVID-19 mRNA vaccination. Vaccine (Basels). 2022;10:43.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.